Zobrazeno 1 - 10
of 34
pro vyhledávání: ''
Autor:
Kausar Suleman, Noha Jastaniyah, Tusneem Elhassan, Wafa Alkhayal, Osama Almalik, Ali Hassan Mushtaq, Adher Al-Sayed, Dahish Ajarim, Emaan Haque, Taher Al-Tweigeri, Ahmed Badran
Publikováno v:
Oncology. 98:168-173
Background:There is a paucity of literature examining the impact of timing of surgery after neoadjuvant chemotherapy. Objective:This study aimed to analyze the impact of the time taken to initiate surgical treatment following completion of neoadjuvan
Autor:
Chikage Iguchi, Eiichi Shiba, Noriko Fujita, Keiko Inakami, Hitoshi Yamamoto, Tsutomu Kasugai, Takashi Nomura, Tetsu Yanagisawa, Yukie Enomoto, Toyokazu Aono
Publikováno v:
Oncology. 98:35-41
Background: It is unclear for whom new anti-human epidermal growth factor receptor 2 (anti-HER2) agents, such as pertuzumab and T-DM1, should be considered. We investigated prognostic factors before neoadjuvant chemotherapy (NAC) among HER2-positive
Autor:
Sara Alfieri, Rosalba Miceli, Paola Mariani, Giulia Bianchi, Gabriele Infante, Marco Bosisio, Claudio Vernieri, Giuseppe Capri, Claudia Borreani
Publikováno v:
Oncology. 99(2)
Background: Aromatase inhibitors (AIs) as adjuvant therapy after breast cancer (BC) surgery have demonstrated to reduce the risk of disease recurrence, to lower the risk of contralateral BC, and to improve survival when compared to tamoxifen in patie
Autor:
Maria Blettner, Rolf Kreienberg, Catharina Bartmann, Mathias Krockenberger, Achim Wöckel, J Diessner, Sebastian Häusler, Tanja Stüber, I. Novopashenny, Manfred Wischnewsky, Roland Stein, Wolfgang Janni
Publikováno v:
Oncology. 92:317-324
Objective: To identify subgroups of patients with pT1 pN0 breast cancer (BC) who might not profit from adjuvant systemic therapy (AST). Methods: Data of 3,774 pT1 pN0 BC patients from 17 certified BC centres within the BRENDA study group were collect
Autor:
Jae Hong Seo, Sang Won Shin, Yeul Hong Kim, Yoon Ji Choi, Kyong Hwa Park, Keun Seok Lee, Suk Young Lee, Jun Suk Kim, Hyesook Kim, In Hae Park, Ju Won Kim
Publikováno v:
Oncology. 91:274-282
Objective: This retrospective study was undertaken to assess the incidence of and risk factors for febrile neutropenia (FN) during adjuvant chemotherapy for early-stage breast cancer (ESBC). Methods: A multicenter survey of three tertiary hospitals w
Autor:
Daniel Shepshelovich, Baruch Brenner, Tzippy Shochat, Shulamit Rizel, Victoria Neiman, Rinat Yerushalmi, Daniel Hendler, Aaron Sulkes, Hadar Goldvaser
Publikováno v:
Oncology. 91:217-223
Purpose: To evaluate the association between angiotensin receptor blocker (ARB) usage and breast cancer characteristics and outcomes. Methods: All patients who were treated in our institute for estrogen receptor-positive, human epidermal growth facto
Autor:
Mamiko Fujisue, Yasuo Toyozumi, Tomofumi Osako, Reiki Nishimura, Nobuyuki Arima, Masahiro Nakano, Yasuyuki Nishiyama, Yasuhiro Okumura, Rumiko Tashima
Publikováno v:
Oncology. 90:43-50
Objective: In this case-control study, we investigated the most suitable cell counting area and the optimal cutoff point of the Ki-67 index. Methods: Thirty recurrent cases were selected among hormone receptor (HR)-positive/HER2-negative breast cance
Publikováno v:
Oncology. 95(4)
Objective: There is insufficient information on predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast carcinoma that also presented clinical complete response (cCR) evaluated in breast, axilla and breast and axi
Autor:
Christian Garbar, Catherine Abrial, Qian Wang-Lopez, Fabrice Kwiatkowski, Armand Bensussan, Sarah Mombelli, Hervé Curé, Paul de Boissieu
Publikováno v:
Oncology. 88:261-272
Objective: Neoadjuvant chemotherapy (NACT) allows for a more frequent use of breast-conservative surgery; it is also an in vivo model of individual tumor sensitivity which permits to determine new prognostic factors to personalize the therapeutic app
Autor:
Masakatsu Onozawa, Noriaki Wada, Hirofumi Mukai, Keiji Nihei, Toshiyuki Shimada, Shunji Nagai, Mikiya Ishihara
Publikováno v:
Oncology. 84:135-140
Objective: Identifying factors that predispose patients to central nervous system (CNS) metastases may hasten disease detection and improve treatment outcomes. Methods: We reviewed the records of patients who were diagnosed with clinical stage I–II